British regulators on Thursday said they have identified 30 cases of rare blood clot events after the use of AstraZeneca’s coronavirus vaccine, 25 more than the agency previously reported.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it had received no such reports of blood clotting events following use of the vaccine made by BioNTech SE and Pfizer Inc.

On Friday, the medicine regulator told the Financial Times and The Guardian that 7 recipients of the AstraZeneca vaccine have died after registering the rare blood clotting events. Reuters was not immediately able to confirm the number from MHRA after office hours.

MHRA, European Medicines Agency and the World Health Organization (WHO) have reiterated that the vaccine’s benefits in the prevention of the coronavirus far outweigh any potential risk of blood clots.

Some countries are restricting use of the AstraZeneca vaccine while others have resumed inoculations, as investigations into reports of rare, and sometimes severe, blood clots continue.

The UK medicines regulator said, on March 18, that there had been 5 cases of a rare brain blood clot among 11 million administered doses.

On Thursday, it put the count at 22 reports of cerebral venous sinus thrombosis, an extremely rare brain clotting ailment, and 8 reports of other clotting events associated with low blood platelets out of a total of 18.1 million shots given.